⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4218735 | 0.76 | — | — | |
| SCHEMBL21948056 | 0.76 | CCNA2 (0.32) | — | |
| SCHEMBL855838 | 0.75 | HPGD (0.36) | — | |
| SCHEMBL29563716 | 0.73 | APP (0.35) | — | |
| SCHEMBL23147880 | 0.72 | — | — | |
| SCHEMBL29721900 | 0.72 | — | — | |
| SCHEMBL417021 | 0.70 | CCR1 (0.40) | — | |
| SCHEMBL29722426 | 0.70 | — | — | |
| SCHEMBL23148094 | 0.70 | — | — | |
| SCHEMBL28453444 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| US-9593115-B2 | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof | ADVINUS THERAPEUTICS LTD. | 2017-03-14 | — | — | US | disclosed |
| US-9593115-B2 | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof | ADVINUS THERAPEUTICS LTD. | 2017-03-14 | — | — | US | disclosed |
| US-20150239886-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-27 | — | — | US | disclosed |
| US-20150239886-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-27 | — | — | US | disclosed |
| EP-2897962-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014045305-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-03-27 | — | — | WO | disclosed |